ASA404 to be developed in breast cancer

LONDON, UK, Feb 12, 2009 (MARKET WIRE via COMTEX) ----London, UK, and Cambridge,
MA, 12 February 2009 - Antisoma plc (LSE: ASM; USOTC:ATSMY) announces that its Tumour-
Vascular Disrupting Agent, ASA404, will be evaluated by Novartis as a treatment for HER2-
negative metastatic breast cancer. This indication is being prioritised ahead of prostate cancer, in
which a phase II trial has been completed. Details of the plans for trials in breast cancer will be
available later this year.

Antisoma and Novartis have a worldwide development and commercialisation agreement for
ASA404. Trials in breast cancer will be in addition to two ongoing pivotal phase III trials in
patients with non-small cell lung cancer, one (ATTRACT-1) testing ASA404 as a first-line
treatment and the other (ATTRACT-2) evaluating ASA404 as a second-line treatment. Because
ASA404 acts by disrupting tumour blood vessels, it has potential application against a variety of
solid tumours, all of which depend on tumour blood vessels to survive and grow.

Glyn Edwards, Antisoma's CEO, said: "We are very pleased that Novartis is extending the
development of ASA404 to metastatic breast cancer. This represents a significant additional
opportunity for ASA404. While there have been many advances in the treatment of breast cancer,
there remains a great need for new and innovative approaches, especially for patients with
metastatic cancer."

About metastatic breast cancer

Worldwide, more than a million women are diagnosed with breast cancer and over 400,000 die
from the disease each year. Metastatic breast cancer is the most advanced stage (stage IV).
Over 100,000 patients present with stage IV disease each year in the US, Europe and Japan.

About ASA404

ASA404 (DMXAA: undefined, undefined, undefined%) is a small-molecule Tumour-Vascular

Disrupting Agent (Tumour-VDA) which selectively targets the blood vessels that nourish tumours.
The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the
Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-
licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research
Technology), the development and commercialisation company of the Cancer Research
Campaign (now Cancer Research UK), in August 2001. In a randomised phase II study in non-
small cell lung cancer, addition of ASA404 to standard first-line chemotherapy was associated
with a 5 month improvement in median survival. Worldwide rights to the drug were licensed to
Novartis AG in April 2007.

About Antisoma

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel

products for the treatment of cancer. The Company has operations in the UK and the US. Please
visit www.antisoma.com for further information about Antisoma.

Enquiries:

Glyn Edwards, CEO

Daniel Elger, VP, Marketing & Communications +44 (0)7909 915 068
Antisoma plc
 Mark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 5000
Dietrich
Buchanan Communications
Brian Korb +1 646 378 2923
The Trout Group

Except for the historical information presented, certain matters discussed in this statement are
forward looking statements that are subject to a number of risks and uncertainties that could
cause actual results to differ materially from results, performance or achievements expressed or
implied by such statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical development
programmes, the expected timing of clinical trials and regulatory filings. Such statements are
based on management's current expectations, but actual results may differ materially.

---END OF MESSAGE---

This announcement was originally distributed by Hugin. The issuer is solely responsible for the
content of this announcement.

Copyright Copyright Hugin AS 2009. All rights reserved.